| 摘要 |
<p>#CMT# #/CMT# Use of a pharmaceutical composition having enantiomer of (amino-7-triethoxy-4,5,6-oxo-1-dihydro-1,3-isobenzofurannyl-3)-1-methoxy-8 methyl-2-methylenedioxy-6-6,7-tetrahydro-2,3,4-isoquinoline (tritoqualine) or its salts and a proton pump inhibitor (PPI) to make a drug to treat digestive inflammatory conditions, particularly diseases related to hypersecretion of digestive juices, e.g. gastritis, gastric ulcer, gastro-oesophageal reflux, oesophagitis, duodenitis, dyspepsia, particularly irritable colon syndrome. This anti-secretory composition reduces all carcinogenic risks and infections. #CMT#ACTIVITY : #/CMT# Anti-inflammatory; Antiallergic; Immunosuppressive; Gastrointestinal-Gen; Antiulcer. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# The composition is useful to prepare the medicament to treat digestive inflammatory conditions, particularly hypersecretion of digestive juices, e.g. gastritis, gastric ulcer, gastro-oesophageal reflux, oesophagitis, duodenitis and dyspepsia, particularly irritable colon syndrome (claimed). The ability of tritoqualine to treat irritable colon syndrome was tested in human. The result showed that the symptoms such as abdomen pain and anaemia was reduced after three weeks of the treatment. #CMT#ADVANTAGE : #/CMT# The composition decreases all carcinogenic risks and infections (claimed) (particularly bacterial infections). #CMT#PHARMACEUTICALS : #/CMT# Preferred Components: PPI is omeprazole, esomeprazole, pantoprazole, lansoprasole (preferred) or rebeprazole. #CMT#ADMINISTRATION : #/CMT# Administration of: tritoqualine is 100-600 mg, preferably 100-200 mg; PPI is 10-80 mg, (preferably lansoprasole at 10-20 mg); or the composition is 10-20 mg, in the form of tablet, lozenge, gel and capsule (claimed) by any suitable route.</p> |
